Cure8 research brief
Noninvasive GI ultrasound (including Doppler/CEUS) could reduce the need for frequent endoscopies for monitoring IBD activity and, when combined with biomarkers, may improve accuracy of disease assessment. However, current evidence is heterogeneous and not strong enough to replace endoscopy.
Clinicians, researchers, adult patients with IBD, patients on biologic therapy, and caregivers interested in noninvasive monitoring
This scoping review summarizes studies (2018–March 2026) assessing gastrointestinal ultrasound (GIUS), including Doppler and contrast-enhanced ultrasound (CEUS), for measuring IBD activity compared with endoscopy and biomarkers.
Published meta-analyses cited in the review report pooled sensitivity ~85–91% and specificity ~83–96% for GIUS versus endoscopy; the review itself did not perform new pooled estimates.
Bowel wall thickness (>3 mm) was the most commonly used ultrasound parameter; Doppler/CEUS add vascularity and perfusion information and CEUS showed the highest reported accuracy in existing meta-analytic literature, though data are limited.
The authors conclude GIUS (alone or combined with biomarkers) looks promising, particularly in moderate-to-severe disease and for monitoring, but evidence is heterogeneous, of unassessed quality, and lacks randomized trials. They do not recommend replacing endoscopy based on current data and call for standardized protocols and randomized studies.
This is a scoping review summarizing studies and existing meta-analyses through March 2026; it did not perform a formal risk-of-bias assessment or new pooled statistical analyses. Findings highlight potential but call for standardized protocols and randomized trials.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
RDW is part of a routine complete blood count and, if reliably associated with IBD activity, could offer a low-cost, widely available adjunctive biomarker for detecting disease and monitoring activity.
Non-invasive biomarkers can help detect and monitor IBD activity, distinguish IBD from other GI conditions, and potentially predict relapse—tools that may reduce need for invasive tests.
The review suggests RDW, an inexpensive and widely available blood test parameter, is higher in IBD and correlates with disease activity—meaning it might help clinicians monitor disease alongside other tests.
